MedTrace Logo

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC

NCT02999646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this trial is to determine the efficacy of the immunotherapy with MVX-ONCO-1 in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 consists of dead tumor cells from the patient itself and genetically modified cells within a capsule. The whole treatment takes 9 weeks. At weeks 1, 2, 3, 4, 6 and 8, the tumor cells are injected underneath the skin and two capsules are implanted for a week. At weeks 2, 3, 4, 5, 7 and 9 the capsules are removed again. The patients are then followed-up for 5 years.

Conditions

Interventions

OTHER

MVX-ONCO-1

Autologous cells: 1 vial containing 4x10\^6 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x10\^5 MVX-1 cells

Sponsors & Collaborators

Principal Investigators

  • Olivier Michielin, Prof · CHUV Lausanne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-25
Primary Completion
2023-01-25
Completion
2023-06-29

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02999646 on ClinicalTrials.gov